Orris

Typhoid injectable treatment

Reading File
Finding Sources
Finding Sources
Searching PubMed

"typhoid fever" AND ceftriaxone

Searching the Web

typhoid fever IV injectable antibiotic treatment ceftriaxone dose guideline

Injectable (Parenteral) Treatment for Typhoid Fever

First-line severe/complicated cases or when oral therapy isn't possible:
Ceftriaxone (IV/IM) - drug of choice for severe, multidrug-resistant, or hospitalized cases
  • Adults: 2 g IV once daily (up to 4 g/day in severe disease), typically for 10-14 days, or 1 g every 12 hours
  • Children: 50-75 mg/kg/day (max 2-4 g/day) IV once daily or divided q12h, for 7-14 days
  • Continue until defervescence, then can often switch to oral agent (step-down therapy)
  • Also effective as short-course outpatient therapy: single dose of 3-4 g over 1-2 days has shown good efficacy in uncomplicated cases (Tintinalli's Emergency Medicine; MSF Guidelines)
Cefotaxime (IV) - alternative third-generation cephalosporin, similar efficacy to ceftriaxone
Chloramphenicol (IV) - historically the first effective agent, reduced mortality from ~20% to under 1%, but largely abandoned now due to bone marrow toxicity and widespread resistance (Sherris & Ryan's Medical Microbiology). Still used in resource-limited settings: 50-75 mg/kg/day IV/IM in divided doses for 14 days.
Ampicillin (IV) - alternative for susceptible strains, especially historically used with chloramphenicol/TMP-SMX.
Fluoroquinolones (IV ciprofloxacin) - effective but fluoroquinolone resistance is increasing globally, so use guided by local susceptibility data (Tintinalli's Emergency Medicine).

Notes on relapse and resistance

  • Relapse rates were higher with chloramphenicol, ampicillin, and TMP-SMX; notably lower (<5%) with ceftriaxone and fluoroquinolones (Goldman-Cecil Medicine).
  • Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Salmonella Typhi strains are increasingly common, which is why ceftriaxone/cefotaxime have become preferred empiric injectable options in many regions, especially South Asia (Sherris & Ryan's Medical Microbiology; Harrison's Principles of Internal Medicine).
  • Azithromycin (oral, not injectable) is often preferred for uncomplicated cases where fluoroquinolone/MDR resistance is a concern, with relapse rates lower than fluoroquinolones or ceftriaxone in some studies (Yamada's Textbook of Gastroenterology).

Severe disease (e.g., typhoid with altered consciousness, shock)

  • High-dose dexamethasone plus antibiotics has historically been used in severe toxic typhoid, alongside IV ceftriaxone.

Recent evidence check

A 2025 Cochrane systematic review (PMID: 40326553) focuses on typhoid conjugate vaccines for prevention rather than treatment, and a 2024 systematic review (PMID: 39623850) compared oral azithromycin versus other antimicrobials (including ceftriaxone, chloramphenicol, fluoroquinolones) - worth checking if you want vaccine-related or oral-vs-injectable comparative data specifically, as these don't contradict the injectable regimens above but focus on different comparisons.
Important: Actual choice of injectable antibiotic should be guided by local antimicrobial resistance patterns and blood culture sensitivity results whenever possible, given rising MDR/XDR S. Typhi. This is general clinical information, not a substitute for a treating physician's assessment of the specific patient.
This is a shared conversation. Sign in to Orris to start your own chat.